Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00329355 · ClinicalTrials.gov registry record · Phase 3
Menstrual Migraine Treatment With TREXIMET (Formerly Known as TREXIMA)
A Phase 3 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 3
- Development phase
- 351
- Enrollment target
NCT00329355 is a Phase 3 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 351 participants.
The verdict
NCT00329355, a Phase 3 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 351 participants
- Enrollment target
Study Summary
This study was designed to determine efficacy of TREXIMET (sumatriptan/naproxen sodium), formerly known as TREXIMA compared to placebo for the treatment of a menstrual migraine.
Interventions
- DRUG sumatriptan succinate/naproxen sodium
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 351 participants |
| Start Date | 2006-05 |
| Est. Completion | 2006-11 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00329355
The ClinicalTrials.gov registry entry for NCT00329355 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 351 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which sumatriptan succinate/naproxen sodium is the first listed.
NCT00329355 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00329355 about?
NCT00329355 is a clinical study titled "Menstrual Migraine Treatment With TREXIMET (Formerly Known as TREXIMA)". This study was designed to determine efficacy of TREXIMET (sumatriptan/naproxen sodium), formerly known as TREXIMA compared to placebo for the treatment of a menstrual migraine.
What is the current status of trial NCT00329355?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 351 participants. The study started on 2006-05. Estimated completion is 2006-11.
What interventions are being tested in trial NCT00329355?
The interventions under investigation include: sumatriptan succinate/naproxen sodium (DRUG).
Who is sponsoring clinical trial NCT00329355?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.